B & T Capital Management DBA Alpha Capital Management Has $3.69 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

B & T Capital Management DBA Alpha Capital Management grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,157 shares of the medical research company’s stock after purchasing an additional 623 shares during the quarter. B & T Capital Management DBA Alpha Capital Management’s holdings in Amgen were worth $3,690,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AMGN. Waterloo Capital L.P. acquired a new stake in shares of Amgen in the 2nd quarter valued at approximately $231,000. Seven Eight Capital LP bought a new stake in Amgen in the second quarter valued at approximately $845,000. XTX Topco Ltd acquired a new stake in Amgen in the second quarter worth $661,000. Intech Investment Management LLC boosted its position in shares of Amgen by 48.9% during the second quarter. Intech Investment Management LLC now owns 53,109 shares of the medical research company’s stock worth $16,594,000 after purchasing an additional 17,436 shares in the last quarter. Finally, Ieq Capital LLC raised its stake in Amgen by 7.8% during the 2nd quarter. Ieq Capital LLC now owns 51,921 shares of the medical research company’s stock worth $16,222,000 after buying an additional 3,757 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Royal Bank of Canada decreased their target price on Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Piper Sandler lowered their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Leerink Partners lowered their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective on shares of Amgen in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Stock Up 1.0 %

AMGN opened at $272.11 on Friday. The stock’s fifty day simple moving average is $275.01 and its 200 day simple moving average is $307.49. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock has a market cap of $146.27 billion, a PE ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the company posted $4.96 EPS. As a group, research analysts expect that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.50%. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.